Cytokinetics Inc

CYTK

Add to Watchlist

77.220USD

+2.410+3.22%

Close 05/13, 16:00（ET）Quotes delayed by 15 min

Cytokinetics Inc's Score

Industry at a Glance

Industry Ranking

40 / 383

Overall Ranking

140 / 4490

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cytokinetics Inc Highlights

StrengthsRisks

Cytokinetics, Incorporated is a late-stage, specialty cardiovascular biopharmaceutical company focused on discovering, developing and commercializing muscle biology-directed drug candidates as potential treatments for debilitating diseases in which cardiac muscle performance is compromised. The Company is engaged in the commercialization of aficamten, a cardiac myosin inhibitor, and is being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive hypertrophic cardiomyopathy. The Company is also developing omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF); CK-586, a cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 1069.18% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 88.04M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 88.04M.

Undervalued

The company’s latest PE is -10.93, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 147.01M shares, decreasing 9.22% quarter-over-quarter.

Held by Murray Stahl

Star Investor Murray Stahl holds 15.40K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.84.

Analyst Rating

Based on 21 analysts

Buy

Current Rating

102.444

Target Price

+33.20%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Cytokinetics Inc is 5.07, ranking 371 out of 383 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 19.36M, representing a year-over-year increase of 1125.78%, while its net profit experienced a year-over-year increase of 27.67%.

Score

Industry at a Glance

Previous score

5.07

Change

0



Financials

3.60

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

7.48

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

4.44

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Cytokinetics Inc is 6.60, ranking 239 out of 383 in the Biotechnology & Medical Research industry. Its current P/E ratio is -10.93, which is -55.66% below the recent high of -4.85 and -81.36% above the recent low of -19.82.

Score

Industry at a Glance

Previous score

6.60

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 40/383

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Cytokinetics Inc is 8.00, ranking 161 out of 383 in the Biotechnology & Medical Research industry. The average price target is 79.00, with a high of 120.00 and a low of 55.00.

Score

Industry at a Glance

Previous score

8.00

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Cytokinetics Inc is 9.37, ranking 26 out of 383 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 83.79 and the support level at 62.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.29

Change

0.08

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-05-12

The current institutional shareholding score of Cytokinetics Inc is 10.00, ranking 1 out of 383 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 109.63%, representing a quarter-over-quarter decrease of 17.29%. The largest institutional shareholder is PRFDX, holding a total of 1.82M shares, representing 1.34% of shares outstanding, with 15.71% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

T. Rowe Price Investment Management, Inc.

17.72M

-7.15%

BlackRock Institutional Trust Company, N.A.

13.99M

+2.80%

Fidelity Management & Research Company LLC

9.47M

+0.42%

Wellington Management Company, LLP

7.94M

+7.13%

State Street Investment Management (US)

5.83M

+3.70%

Deep Track Capital LP

3.34M

-22.40%

Geode Capital Management, L.L.C.

3.06M

+0.52%

BofA Global Research (US)

2.88M

-4.42%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cytokinetics Inc is 6.92, ranking 19 out of 383 in the Biotechnology & Medical Research industry. The company's beta value is 0.37. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Cytokinetics Inc

CYTK

7.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.75 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Krystal Biotech Inc

KRYS

8.60 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.54 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Exelixis Inc

EXEL

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Ascendis Pharma A/S

ASND

8.45 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment